
Merrimack Pharmaceuticals Inc (MACK) - Financial and Strategic SWOT Analysis Review
Description
Merrimack Pharmaceuticals Inc (MACK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Merrimack Pharmaceuticals Inc (Merrimack) is a clinical-stage biopharmaceutical company that develops and commercializes novel targeted solutions for the treatment of various types of cancers through its understanding of biological markers and cancer pathways. Its first commercial product, Onivyde (irinotecan liposome injection), is a liposomal formulation for the treatment of advanced pancreatic cancer patients. Merrimack is headquartered in Cambridge, Massachusetts, the US.
Merrimack Pharmaceuticals Inc Key Recent Developments
Mar 09,2023: Merrimack Reports Full Year 2022 Financial Results
Nov 03,2022: Merrimack Reports Third Quarter 2022 Financial Results
Aug 04,2022: Merrimack Reports Second Quarter 2022 Financial Results
May 05,2022: Merrimack Reports First Quarter 2022 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Financial ratio pr SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
39 Pages
- Section 1 - About the Company
- Merrimack Pharmaceuticals Inc - Key Facts
- Merrimack Pharmaceuticals Inc - Key Employees
- Merrimack Pharmaceuticals Inc - Key Employee Biographies
- Merrimack Pharmaceuticals Inc - Major Products and Services
- Merrimack Pharmaceuticals Inc - History
- Merrimack Pharmaceuticals Inc - Company Statement
- Merrimack Pharmaceuticals Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Merrimack Pharmaceuticals Inc - Business Description
- Merrimack Pharmaceuticals Inc - SWOT Analysis
- SWOT Analysis - Overview
- Merrimack Pharmaceuticals Inc - Strengths
- Merrimack Pharmaceuticals Inc - Weaknesses
- Merrimack Pharmaceuticals Inc - Opportunities
- Merrimack Pharmaceuticals Inc - Threats
- Merrimack Pharmaceuticals Inc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Merrimack Pharmaceuticals Inc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Mar 09, 2023: Merrimack Reports Full Year 2022 Financial Results
- Nov 03, 2022: Merrimack Reports Third Quarter 2022 Financial Results
- Aug 04, 2022: Merrimack Reports Second Quarter 2022 Financial Results
- May 05, 2022: Merrimack Reports First Quarter 2022 Financial Results
- Mar 09, 2022: Merrimack Reports Full Year 2021 Financial Results
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Merrimack Pharmaceuticals Inc, Key Facts
- Merrimack Pharmaceuticals Inc, Key Employees
- Merrimack Pharmaceuticals Inc, Key Employee Biographies
- Merrimack Pharmaceuticals Inc, Major Products and Services
- Merrimack Pharmaceuticals Inc, History
- Merrimack Pharmaceuticals Inc, Subsidiaries
- Merrimack Pharmaceuticals Inc, Key Competitors
- Merrimack Pharmaceuticals Inc, Ratios based on current share price
- Merrimack Pharmaceuticals Inc, Annual Ratios
- Merrimack Pharmaceuticals Inc, Annual Ratios (Cont...1)
- Merrimack Pharmaceuticals Inc, Interim Ratios
- Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Merrimack Pharmaceuticals Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Merrimack Pharmaceuticals Inc, Performance Chart (2018 - 2022)
- Merrimack Pharmaceuticals Inc, Ratio Charts
- Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Merrimack Pharmaceuticals Inc,
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.